Logo

Sana Entered into an Agreement with Beam for Non-Exclusive Commercial Rights of its CRISPR Cas12b Nuclease System for Cell Therapy Programs

Share this

Sana Entered into an Agreement with Beam for Non-Exclusive Commercial Rights of its CRISPR Cas12b Nuclease System for Cell Therapy Programs

Shots:

  • Beam to receive $50M up front & is eligible to receive a target option exercise fees- milestones upon achievement of development & sales milestones along with royalties on sales of products
  • The agreement will combine Beam’s gene-editing technology with Sana’s ex vivo platform to use the Cas12b system for ex vivo engineered cell therapy programs
  • Sana gets a non-exclusive right to use Beam’s Cas12b system with allogeneic T cell & stem cell-derived programs & can make gene edits for Sana’s hypoimmune platform. Cas12b is a CRISPR-based nuclease with a high degree of specificity & efficiency which can be used to knock out & knock-in genes in certain cell types

  | Ref: Globe Newswire | Image: Holdereauz Studio

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions